| Literature DB >> 33237337 |
Mathijs R Wirtz1,2,3, Jiri Moekotte4,5, Kirsten Balvers4,5,6, Marjolein M Admiraal4,5, Jean-Francois Pittet7, Joe Colombo8, Brant M Wagener7, J Carel Goslings9, Nicole Juffermans4,5.
Abstract
PURPOSE: Nosocomial infection contributes to adverse outcome after brain injury. This study investigates whether autonomic nervous system activity is associated with a decreased host immune response in patients following stroke or traumatic brain injury (TBI).Entities:
Keywords: Autonomic nervous system; Brain injury; Immunosuppression; Nosocomial infection
Year: 2020 PMID: 33237337 PMCID: PMC7688871 DOI: 10.1186/s40635-020-00359-3
Source DB: PubMed Journal: Intensive Care Med Exp ISSN: 2197-425X
Baseline characteristics of brain injured patients
| All patients ( | Infected ( | Non-infected ( | |
|---|---|---|---|
| Main characteristics | |||
| Age (years, | 51 (19.3) | 52 (18.2) | 50 (20.1) |
| Male gender ( | 47 (73%) | 15 (65%) | 32 (78%) |
| Reason for ICU admission ( | |||
| TBI | 50 (78%) | 18 (78%) | 32 (78%) |
| iCVA | 9 (14%) | 2 (9%) | 7 (17%) |
| hCVA | 5 (8%) | 3 (13%) | 2 (5%) |
| Admission injury/illness severity scores | |||
| ISS (mean, SD) | 24 (11) | 26 (12) | 23 (11) |
| AIS thorax ≥ 3 ( | 13 (26%) | 5 (28%) | 8 (25%) |
| AIS abdomen/pelvis ≥ 3 ( | 2 (4%) | 1 (6%) | 1 (3%) |
| AIS extremity ≥ 3 ( | 4 (8%) | 0 (0%) | 4 (13%) |
| AIS external ≥ 3 ( | 0 (0%) | 0 (0%) | 0 (0%) |
| GCS (median, IQR) | 7 (3–9) | 7 (3–8) | 6 (3–9) |
| SAPS 2 (mean, SD) | 43.7 (11.3) | 45.5 (9.3) | 42.7 (12.3) |
| APACHE II (median, IQR) | 19 (16–23) | 19 (17–21) | 19 (15–23) |
| Comorbidity | |||
| Prehospital beta-blocker use ( | 10 (16%) | 4 (17%) | 6 (15%) |
| Hypertension ( | 14 (22%) | 5 (22%) | 9 (22%) |
| CVA ( | 6 (9%) | 3 (13%) | 3 (7%) |
| Cardiac pathology ( | 11 (17%) | 3 (13%) | 8 (20%) |
| Diabetes mellitus ( | 6 (9%) | 2 (9%) | 4 (10%) |
| COPD ( | 4 (6%) | 1 (4%) | 3 (7%) |
| Alcohol abuse ( | 5 (8%) | 2 (9%) | 3 (7%) |
| Admission clinical parameters | |||
| Heart rate (bpm, mean, SD) | 80 (17) | 83 (15) | 79 (18) |
| SBP (mmHg, mean, SD) | 132 (29) | 132 (37) | 133 (24) |
| Temperature (°C, mean, SD) | 35.6 (1.2) | 35.5 (1.3) | 35.7 (1.2) |
| Admission lab parameters | |||
| Hb (mmol/l, median, IQR) | 7.9 (6.7–8.5) | 7.2 (6.3–8.2)* | 8.0 (7.5–8.8) |
| WCC (× 10^9/l, mean SD) | 11.8 (4.7) | 11.6 (5.8) | 11.9 (4.0) |
| CRP (mg/l, median, IQR) | 3.8 (0.7–6.7) | 3.8 (2–7.4) | 4.9 (0.6–7.8) |
Data are presented as mean standard deviation, median and interquartile range or absolute number and percentage
ICU intensive care unit, TBI traumatic brain injury, iCVA ischemic cerebrovascular accident, hCVA hemorrhagic cerebrovascular accident, ISS Injury Severity Score, AIS Abbreviated Injury Scale, GCS Glasgow Coma Score, SOFA Sequential Organ Failure Assessment Score, SAPS 2 Simplified Acute Physiology Score 2, APACHE II Acute Physiology and Chronic Health Evaluation 2 score, MI myocardial infarction, AF atrial fibrillation, COPD chronic obstructive pulmonary disease, SBP systolic blood pressure, Hb hemoglobin, WCC white cell count, CRP C-reactive protein
*Significantly different from non-infected group
†Cardiac pathology includes MI and AF, as well as cardiac valve pathology and other (paroxysmal) rhythm disorders
Fig. 1Pathogens found in positive microbiology cultures. HAP hospital acquired pneumonia, SSI surgical site infection, UTI urinary tract infection, BSI blood stream infection, IA intracranial abscess
Treatment on ICU and outcome
| All patients ( | Infected ( | Non-infected ( | ||
|---|---|---|---|---|
| Invasive procedures | ||||
| Surgery ( | 38 (59) | 17 (74) | 21 (51) | 0.076 |
| Amount of surgical procedures ( | 1 (0–1) | 1 (0–3) | 1 (0–1) | 0.006 |
| Tracheostomy ( | 10 (16) | 8 (35) | 2 (5) | 0.002 |
| Intracranial device ( | 20 (31) | 12 (52) | 8 (20) | 0.007 |
| Duration of Intracranial device (days, median, IQR) | 0 (0–2) | 1 (0–6) | 0 (0–0) | 0.005 |
| Central venous catheter ( | 26 (41) | 12 (52) | 14 (34) | 0.159 |
| Duration of central venous catheter (days, median, IQR) | 0 (0–5) | 2 (0–8) | 0 (0–3) | 0.103 |
| Treatment during ICU/CMC stay | ||||
| Antibiotics ( | 48 (75) | 19 (83) | 29 (71) | 0.292 |
| SDD ( | 44 (69) | 18 (78) | 26 (63) | 0.219 |
| Other than SDD ( | 37 (58) | 16 (70) | 21 (51) | 0.154 |
| Duration of antibiotics (days, median, IQR) | 5 (1–7) | 5 (2–9) | 4 (0–7) | 0.126 |
| Vasopressor ( | 35 (55) | 17 (74) | 18 (44) | 0.021 |
| Duration of vasopressor use (days, median, IQR) | 1 (0–2) | 1 (0–5) | 0 (0–2) | 0.016 |
| Beta-blocker ( | 12 (19) | 7 (30) | 5 (12) | 0.073 |
| Duration of beta-blocker use (days, median, IQR) | 0 (0–0) | 0 (0–2) | 0 (0–0) | 0.066 |
| Mechanically ventilated ( | 61 (95) | 23 (100) | 38 (93) | 0.184 |
| Duration of ventilation (days, median, IQR) | 3 (2–7) | 6 (2–11) | 2 (2–5) | 0.042 |
| Outcome | ||||
| Onset of (first) infection (days, median, IQR) | NA | 6 (3–12) | NA | NA |
| ICU stay (days, median, IQR) | 4.5 (3–9) | 8 (3–14) | 4 (2–6.5) | 0.011 |
| Total length of hospital stay (days, median, IQR) | 12 (6–26) | 24 (10–44) | 9 (5–17) | 0.001 |
| Discharge location ( | ||||
| Home | 20 (31) | 4 (17) | 16 (39) | 0.073 |
| Another hospital | 17 (27) | 8 (35) | 10 (24) | 0.375 |
| Nursing home | 14 (22) | 7 (30) | 7 (17) | 0.215 |
| 28-day mortality ( | ||||
| All causes | 12 (19) | 4 (17) | 8 (19) | 0.835 |
| Brain injury | 10 (8) | 3 (13) | 7 (16) | 0.670 |
| MOF | 2 (3) | 1 (4) | 1 (2) | 0.674 |
Data are presented as median and interquartile range or absolute number and percentage
SDD selective decontamination of the digestive tract, ICU intensive care unit
Fig. 2Cytokine production after ex vivo whole blood stimulation. Cytokine production after whole blood stimulation with LPS for samples collected on admission, and 1 and 3 days after admission to the ICU. Values are represented as mean and standard deviation. a TNF-α production measured after 24 h of incubation time. b IL-10 production measured after 24 h of incubation time. c Experimental set-up of whole blood stimulations. Healthy = whole blood stimulations with LPS and incubated with plasma samples of healthy volunteers. Non-infected = whole blood stimulations with LPS incubated with plasma samples of patients without an infection. Infected = whole blood stimulations with LPS incubated with plasma samples of patients with a probable or definite infection. Negative controls = whole blood buffered with RPMI without LPS and without the addition of patient plasma. Positive control = whole blood stimulation with LPS without the addition of patient plasma. †p < 0.10; *p < 0.05; **p < 0.01; ***p < 0.001 compared to all other measurements
Admission HRV parameters
| HRV parameter | Infected ( | Not infected ( | |
|---|---|---|---|
| LF (msec2, median, IQR) | 53 (5–121) | 117 (58–339) | 0.029 |
| HF (msec2, median, IQR) | 72 (27–90) | 72 (22–177) | 0.572 |
| TP (msec2, median, IQR) | 349 (97–750) | 353 (247–1218) | 0.446 |
| LF:HF ratio (median, IQR) | 0.93 (0.43–2.45) | 1.82 (1.33–4.36) | 0.065 |
| LFnu (mean, SD) | 0.46 (0.24) | 0.64 (0.18) | 0.033 |
| HFnu (mean, SD) | 0.54 (0.24) | 0.36 (0.18) | 0.033 |
Data are presented as mean and SD or as median and IQR
LF low frequency, HF high frequency, TP total power, LF:HF ratio ratio between low and high frequency, LFnu normalized units of low-frequency power, HFnu normalized units of high-frequency power
Fig. 3Longitudinal trends of heart rate variability. Daily averages of heart rate variability parameters in infected (black-dotted lines) and non-infected patients (black lines). Grey and dotted lines represent normal values in healthy volunteers as previously described in the literature52 (in figure c median and range and in figure b and d mean and standard deviation). a Heart rate in beats per minute presented as mean and standard deviation. b Low frequency normalized units (LFnu) presented as mean and standard deviation. c LF:HF ratio presented as median and interquartile range. d High frequency normalized units (HFnu) presented as mean and standard deviation. e Number of patients included for every time point. †p < 0.10; *p < 0.05